Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq

Published:2017-12 Issue:4 Volume:3 Page:231-240
ISSN:2405-609X
Container-title:Karbala International Journal of Modern Science
language:en
Short-container-title:Karbala International Journal of Modern Science

Author:

Rahem Rahem Mahdy,Abuhmood Adel Abdulhussien,Hussein Luwaa

Publisher

University of Kerbala

Subject

Physics and Astronomy (miscellaneous),Multidisciplinary,Biochemistry, Genetics and Molecular Biology (miscellaneous),Chemistry (miscellaneous),Computer Science (miscellaneous)

Reference42 articles.

1. The development of imatinib as a therapeutic agent for chronic myeloid leukemia;Deininger;Blood,2005

2. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

3. Imatinib in the treatment of chronic myeloid leukemia: current perspectives on optimal dose;Waclaw;Blood Lymphat. Cancer Targets Ther.,2015

4. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia;Quintás-Cardama;Cancer Control,2009

5. Burden of tyrosine kinase inhibitor failure in patients with chronic myeloid leukemia;Kropf;J. Leuk.,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP